{"schema_version":"1","generated_at":"2026-11-06T14:37:41.464Z","data_as_of":null,"url":"https://www.findmykol.com/kol/stephen-noga","json_url":"https://www.findmykol.com/kol/stephen-noga/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"stephen-noga","name":"Stephen Noga","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Takeda","institution_url":"https://www.findmykol.com/institution/takeda","city":"Baltimore","state":"MD","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1023051000","orcid":"0000-0002-9728-0912","openalex":"A5045288167"},"summary":"Stephen Noga is an Oncology physician affiliated with Takeda. OpenAlex indexes 131 publications with 3,635 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":131,"cited_by_count":3635,"h_index":28,"latest_activity_year":2024,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00333008","title":"A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.","phase":"PHASE2","status":"UNKNOWN","role":"Overall official","sponsor":"The Alvin and Lois Lapidus Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT00333008","trial_url":"https://www.findmykol.com/trial/NCT00333008"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2024,"amount_usd":49.19,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1023051000"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1023051000","source":"payments"},"funding":{"award_count":3,"fiscal_years":{"first":1995,"last":2002},"rows_total":22,"shown":3,"withheld":19,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"P30CA006973","title":"Core--Hematopoietic and Therapeutic Support Facility","fiscal_year":2002,"amount_usd":"250404","organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/P30CA006973"},{"project":"P30CA006973","title":"Core--Hematopoietic and Therapeutic Support Facility","fiscal_year":2002,"amount_usd":"250404","organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/P30CA006973"},{"project":"P01CA015396","title":"Core--Hematopoietic &therapeutic support service","fiscal_year":2002,"organization":"JOHNS HOPKINS UNIVERSITY","source_url":"https://reporter.nih.gov/quickSearch/P01CA015396"}],"source":"grants"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","year":2022,"journal":"The Lancet Haematology","source_url":"https://doi.org/10.1016/s2352-3026(22)00103-x","status":"verified"},{"title":"Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib","year":2020,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/j.clml.2020.06.024","status":"verified"},{"title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type","year":2020,"journal":"BMC Cancer","source_url":"https://doi.org/10.1186/s12885-020-07259-5","status":"verified"},{"title":"Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States","year":2018,"journal":"Clinical Lymphoma Myeloma & Leukemia","source_url":"https://doi.org/10.1016/j.clml.2017.12.012","status":"verified"},{"title":"Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy","year":2018,"journal":"Journal of Managed Care & Specialty Pharmacy","source_url":"https://doi.org/10.18553/jmcp.2018.24.10.1019","status":"verified"}],"source":"works"},"contact":{"address_1":"2401 W BELVEDERE AVENUE","address_2":"LAPIDUS CANCER INSTITUTE","city":"Baltimore","state":"MD","zip":"21215","phone":"410-601-4710","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1023051000","source":"identity"},"similar":[{"name":"Borislava G. Pavlova","slug":"borislava-pavlova","institution":"Takeda","url":"https://www.findmykol.com/kol/borislava-pavlova","json_url":"https://www.findmykol.com/kol/borislava-pavlova/profile.json"},{"name":"Warren Winkelman","slug":"warren-winkelman","institution":"Takeda","specialty":"Dermatology","url":"https://www.findmykol.com/kol/warren-winkelman","json_url":"https://www.findmykol.com/kol/warren-winkelman/profile.json"},{"name":"Gary O. Dubin","slug":"gary-dubin","institution":"Takeda","url":"https://www.findmykol.com/kol/gary-dubin","json_url":"https://www.findmykol.com/kol/gary-dubin/profile.json"},{"name":"Chieko Kitada","slug":"chieko-kitada","institution":"Takeda","url":"https://www.findmykol.com/kol/chieko-kitada","json_url":"https://www.findmykol.com/kol/chieko-kitada/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"funding":19,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2007-11-29","collected_at":"2026-11-05T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}